EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Pathological Diagnosis of Thyroid Nodules with Preoperatively Detected TERT Promoter Mutations in the Absence of BRAF V600E : A Bi-Center Series of 52 Cases

Bayan A Alzumaili iD, Ryan Instrum, Anas Alabkaa iD, Peter M Sadow iD, Michael R Tuttle, Bin Xu iD, Luc G T Morris, Ronald A Ghossein

Thyroid® · 2025

DOI: 10.1177/10507256251363450 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Thyroid®, 2025. Verfasst von Bayan A Alzumaili und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Thyroid Nodule, Telomerase, Proto-Oncogene Proteins B-raf, Mutation. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mutations in the promoter region of TERT ( TERTp ) in thyroid nodules with indeterminate cytology are quoted to confer a high (∼80–95%) probability for thyroid carcinoma when detected on genomic classifier (GC) ThyroSeq. TERTp mutations may also occur in benign and low-risk thyroid neoplasms, and the risk of malignancy (ROM) in nodules harboring TERTp mutations without BRAF V600E is unknown. We analyzed the ROM and the surgical diagnosis in a retrospective cohort of thyroid nodules with TERTp treated at two academic medical centers.

Methods

From 2323 patients with ThyroSeq GC performed on preoperative fine needle aspiration samples, 52 cases (2.3%) were identified harboring TERTp mutations without coexisting BRAF V600E .

Results

The surgical diagnosis was obtained from resection ( n = 51) or biopsy ( n = 1, anaplastic thyroid carcinoma). The ROM was 65%. The reviewed diagnoses were benign/low-risk neoplasms in 18 (35%), carcinoma-American Thyroid Association (ATA) low/intermediate-risk in 14 (27%), and carcinoma-ATA high-risk in 20 (38.5%). All 18 benign or low-risk neoplasms had their tumor capsule submitted entirely, and 78% underwent total thyroidectomy. The molecular alterations were substratified into four groups: TERTp alone ( n = 21, 40%), TERTp + RAS ( n = 18, 35%), TERTp + other non- RAS mutation ( n = 8, 15%), and TERTp + RAS + other alterations ( n = 5, 10%), and the ROM for each group was 57%, 78%, 50%, and 80%, respectively. The frequency of a high-risk malignancy, which would often lead to a recommendation for total thyroidectomy, was 9.5%, 44.5%, 37.5%, and 80%, respectively. The frequency of high-risk carcinomas was significantly higher when a nodule harbored TERTp and other concomitant alterations (48%) compared with TERTp alone (9.5%; p = 0.006).

Conclusions

Thirty five percent of TERTp nodules without BRAF V600E are benign/low-risk thyroid neoplasms, leading to their overtreatment. The incidence of high-risk carcinomas increases in TERTp -mutated nodules with the presence of additional mutations. If the indolent histology found in these lesions is confirmed at the behavior level, lobectomy may be sufficient for the initial management of TERTp thyroid nodules without BRAF V600E as long as there is no aggressive clinical or imaging feature. This will spare many patients from the side effects of total thyroidectomy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NoduleTelomeraseProto-Oncogene Proteins B-rafMutationThyroid NeoplasmsHumansFemaleMaleMiddle AgedRetrospective StudiesAdultPromoter Regions, GeneticAgedBiopsy, Fine-NeedleThyroidectomy

Stichwörter der Autor:innen

FNARASTERT promoterThyroSeqthyroid cancerthyroid nodules

Substanzen

TelomeraseProto-Oncogene Proteins B-rafTERT protein, humanBRAF protein, human

Autor:innen und Institutionen

  • Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear, Boston, Massachusetts, USA.
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

ORCID-Profile: Bayan A Alzumaili, Anas Alabkaa, Peter M Sadow, Bin Xu

Förderung

  • NCI NIH HHS

Zitieren

APA

Alzumaili, B. A., Instrum, R., Alabkaa, A., Sadow, P. M., Tuttle, M. R., Xu, B., Morris, L. G. T., & Ghossein, R. A. (2025). Pathological Diagnosis of Thyroid Nodules with Preoperatively Detected TERT Promoter Mutations in the Absence of BRAF V600E : A Bi-Center Series of 52 Cases. Thyroid®. https://doi.org/10.1177/10507256251363450

Vancouver

Alzumaili BA, Instrum R, Alabkaa A, Sadow PM, Tuttle MR, Xu B, et al. Pathological Diagnosis of Thyroid Nodules with Preoperatively Detected TERT Promoter Mutations in the Absence of BRAF V600E : A Bi-Center Series of 52 Cases. Thyroid®. 2025. doi:10.1177/10507256251363450

BibTeX
@article{Alzumaili2025,
  author = {Alzumaili, Bayan A and Instrum, Ryan and Alabkaa, Anas and Sadow, Peter M and Tuttle, Michael R and Xu, Bin and Morris, Luc G T and Ghossein, Ronald A},
  title = {Pathological Diagnosis of Thyroid Nodules with Preoperatively Detected TERT Promoter Mutations in the Absence of BRAF V600E : A Bi-Center Series of 52 Cases},
  journal = {Thyroid®},
  year = {2025},
  doi = {10.1177/10507256251363450}
}
Kostenlos starten →